Celcuity said Revtorpyk is the first drug of its kind to receive FDA approval. "The PI3K/AKT/mTOR, or PAM, pathway is one of the most important targets in cancer, but comprehensiv ...
The U.S. Food and Drug Administration has approved Celcuity's drug for an advanced form of breast cancer, the regulator said on Tuesday, making it the company's first product to gain ...
REVTORPYK (gedatolisib) vial and box REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K ...
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...
Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade, particularly for patients whose tumours harbour mutations in the epidermal ...
MedPage Today on MSN
PAM inhibitor approved for HR-positive breast cancer
Gedatolisib is approved in combination with fulvestrant, with or without palbociclib ...
Approval addresses the ~60% of HR+/HER2− advanced cases with PIK3CA wild-type disease who are ineligible for PI3Kα-selective inhibitors. VIKTORIA-1 met co-primary PFS end points with gedatolisib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results